We applied the ML-CDN2 model to the gene expression data from TCGA BC samples that did not have drug response data and predicted the response to seven drugs targeting the EGFR signaling pathway: erlotinib, gefitinib, afatinib, cetuximab, lapatinib, CP724714, and pelitinib. This evidence concerns the gene EGFR and breast cancer.